

Global CAR-T Cell Therapy Market, By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others), By Tumor Type (Hematological Malignancies, Solid Tumors), By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others), By Treatment Type (Single Treatment, Combination Treatment), By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), By Region, Competition, Forecast and Opportunities, 2017-2027

<https://marketpublishers.com/r/G6E787582DD0EN.html>

Date: March 2022

Pages: 283

Price: US\$ 4,900.00 (Single User License)

ID: G6E787582DD0EN

Abstracts

Global CAR-T cell therapy market value in the year 2021 was valued at USD1709 million that is anticipated to grow with CAGR of 64.66% during the forecast period, 2023-2027 to achieve market value of USD33153.30 million by 2027F. Increasing instances of cancer among the world population and thus increasing death rate due to cancer is driving the growth of the global CAR-T cell therapy market in the upcoming five years. Rapidly growing clinical trial activities, proliferative M & A activities, and lucrative IPOs are majorly responsible for the growth of the global CAR-T cell therapy

market in the next five years. Consistent researches on cancer and its treatment along with the advancement in the therapeutics are further substantiating the growth of the global CAR-T cell therapy market in the future five years. Increasing demand for the effective cancer treatment for the growing number of people suffering from cancer along with the flourishing pharmaceutical industry producing products and therapies for the cancer are also responsible for the growth of the global CAR-T cell therapy market in the forecast years through 2027. Although side-effects of the CAR-T cells therapy and high cost of treatment making it unaffordable to the financially challenged population may restrain the growth of the market. Government schemes, tax incentives, along with insurance policies for the treatment and increasing number of NGOs working for providing in-expensive treatment to the patients lacking financial support may aid the growth of the global CAR-T cell therapy market in the forecast period.

The global CAR-T cell therapy market is segmented by product type, tumor type, indication, treatment type, targeted antigen, end user, regional distribution, and competition landscape. Based on treatment type, the market is further segmented into single treatment and combination treatment. Single treatment is anticipated to hold the largest revenue shares of the market and dominate the market segment in the upcoming five years on grounds of increasing cases of cancer among the population. Increasing awareness about the cancer diagnostics and early recognition of the tests are responsible for the patients opting for single treatment. Cancer in early stages can be treated with single treatments. The combination treatments are recent developments where multiple therapies are involved together to stop the cancer tumor development, to remove the lumps, and even alter the genetic information.

Gilead Sciences Inc, Novartis International AG, Bristol Myers Squibb Company, AbbVie Inc., Cellectis SA, Amgen Inc, Pfizer Inc, Merck & Co. Inc., Intellia Therapeutics Inc., Poseida Therapeutics Inc, Johnson & Johnson, Allogene Therapeutics Inc, Autolus Therapeutics PLC, Humanigen, Inc, Sangamo Therapeutics, Inc, and among others are among the major market players in the regional platform that lead the market growth of the global CAR-T cell therapy market.

Years considered for this report:

Historical Years: 2017- 2020

Base Year: 2021

Estimated Year: 2022

Forecast Period: 2023 – 2027

Objective of the Study:

To analyze the market size of global CAR-T cell therapy market from 2017 to 2020.

To estimate and forecast the market size of global CAR-T cell therapy market from 2021 to 2022 and growth rate until 2027.

To classify and forecast global CAR-T cell therapy market based on product type, tumor type, indication, treatment type, targeted antigen, end user, regional distribution, and competition landscape.

To identify dominant region or segment in the global CAR-T cell therapy market.

To identify drivers and challenges for global CAR-T cell therapy market.

To examine competitive developments such as expansions, new product & service launches, mergers & acquisitions, etc., in global CAR-T cell therapy market.

To identify and analyze the profile of leading players operating in global CAR-T cell therapy market.

To identify key sustainable strategies adopted by market players in global CAR-T cell therapy market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers & service providers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers & service providers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers & service providers, distribution channels and presence of all major players across the

globe.

TechSci Research calculated the market size of global CAR-T cell therapy market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these products & services and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

Manufacturers & service providers, suppliers

Distributors and other stakeholders

Government bodies such as regulating authorities and policy makers

Organizations, forums and alliances related to CAR-T cell therapy

Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, service providers, suppliers, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global CAR-T cell therapy market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

CAR-T Cell Therapy, By Product Type:

Yescarta (Axicabtagene Ciloleucel)

Kymriah (Tisagenlecleucel)

Tecartus (Brexucabtagene Autoleucel)

Breyanzi (Lisocabtagene Maraleucel)

Abecma (Idecabtagene Vicleucel)

Others

CAR-T Cell Therapy Market, By Tumor Type:

Hematological Malignancies

Solid Tumors

CAR-T Cell Therapy Market, By Indication:

Diffused Large B-Cell Lymphoma (DLBCL)

Acute Lymphoblastic Leukemia (ALL)

Follicular Lymphoma (FL)

Mantle Cell Lymphoma (MCL)

Others

CAR-T Cell Therapy Market, By Treatment Type:

Single Treatment

Combination Treatment

CAR-T Cell Therapy Market, By Targeted Antigen

CD19

BCMA

Others

CAR-T Cell Therapy Market, By End User:

Hospitals

Specialty Clinics

Ambulatory Surgical Centers

Others

CAR-T Cell Therapy Market, By Region:

North America

United States

Canada

Mexico

Europe

Germany

France

United Kingdom

Switzerland

Italy

Spain

Asia-Pacific

China

Japan

India

South Korea

Australia

South America

Columbia

Brazil

Argentina

Middle East & Africa

Israel

Saudi Arabia

South Africa

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global CAR-T cell therapy market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

2. RESEARCH METHODOLOGY

3. IMPACT OF COVID-19 ON GLOBAL CAR-T CELL THERAPY MARKET

4. EXECUTIVE SUMMARY

5. VOICE OF CUSTOMERS

5.1. Brand Awareness

5.2. Unmet Need and Challenges

5.3. Factors Driving the CAR-T Cell Therapy Market

6. GLOBAL CAR-T CELL THERAPY MARKET OUTLOOK

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others)

6.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)

6.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)

6.2.4. By Treatment Type (Single Treatment, Combination Treatment)

6.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)

6.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

6.2.7. By Region

6.2.8. By Company

6.3. Product Market Map

7. NORTH AMERICA CAR-T CELL THERAPY MARKET OUTLOOK

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

- 7.2.1. By Product Type
- 7.2.2. By Tumor Type
- 7.2.3. By Indication
- 7.2.4. By Treatment Type
- 7.2.5. By Targeted Antigen
- 7.2.6. By End User
- 7.2.7. By Country
- 7.3. North America: Country Analysis
 - 7.3.1. United States CAR-T Cell Therapy Market Outlook
 - 7.3.1.1. Market Size & Forecast
 - 7.3.1.1.1. By Value
 - 7.3.1.2. Market Share & Forecast
 - 7.3.1.2.1. By Product Type
 - 7.3.1.2.2. By Tumor Type
 - 7.3.1.2.3. By Indication
 - 7.3.1.2.4. By Treatment Type
 - 7.3.1.2.5. By Targeted Antigen
 - 7.3.1.2.6. By End User
 - 7.3.2. Canada CAR-T Cell Therapy Market Outlook
 - 7.3.2.1. Market Size & Forecast
 - 7.3.2.1.1. By Value
 - 7.3.2.2. Market Share & Forecast
 - 7.3.2.2.1. By Product Type
 - 7.3.2.2.2. By Tumor Type
 - 7.3.2.2.3. By Indication
 - 7.3.2.2.4. By Treatment Type
 - 7.3.2.2.5. By Targeted Antigen
 - 7.3.2.2.6. By End User
 - 7.3.3. Mexico CAR-T Cell Therapy Market Outlook
 - 7.3.3.1. Market Size & Forecast
 - 7.3.3.1.1. By Value
 - 7.3.3.2. Market Share & Forecast
 - 7.3.3.2.1. By Product Type
 - 7.3.3.2.2. By Tumor Type
 - 7.3.3.2.3. By Indication
 - 7.3.3.2.4. By Treatment Type
 - 7.3.3.2.5. By Targeted Antigen
 - 7.3.3.2.6. By End User

8. EUROPE CAR-T CELL THERAPY MARKET OUTLOOK

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Product Type

8.2.2. By Tumor Type

8.2.3. By Indication

8.2.4. By Treatment Type

8.2.5. By Targeted Antigen

8.2.6. By End User

8.2.7. By Country

8.3. Europe: Country Analysis

8.3.1. Germany CAR-T Cell Therapy Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Product Type

8.3.1.2.2. By Tumor Type

8.3.1.2.3. By Indication

8.3.1.2.4. By Treatment Type

8.3.1.2.5. By Targeted Antigen

8.3.1.2.6. By End User

8.3.2. France CAR-T Cell Therapy Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Product Type

8.3.2.2.2. By Tumor Type

8.3.2.2.3. By Indication

8.3.2.2.4. By Treatment Type

8.3.2.2.5. By Targeted Antigen

8.3.2.2.6. By End User

8.3.3. Switzerland CAR-T Cell Therapy Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Product Type

8.3.3.2.2. By Tumor Type

- 8.3.3.2.3. By Indication
- 8.3.3.2.4. By Treatment Type
- 8.3.3.2.5. By Targeted Antigen
- 8.3.3.2.6. By End User
- 8.3.4. United Kingdom CAR-T Cell Therapy Market Outlook
 - 8.3.4.1. Market Size & Forecast
 - 8.3.4.1.1. By Value
 - 8.3.4.2. Market Share & Forecast
 - 8.3.4.2.1. By Product Type
 - 8.3.4.2.2. By Tumor Type
 - 8.3.4.2.3. By Indication
 - 8.3.4.2.4. By Treatment Type
 - 8.3.4.2.5. By Targeted Antigen
 - 8.3.4.2.6. By End User
- 8.3.5. Italy CAR-T Cell Therapy Market Outlook
 - 8.3.5.1. Market Size & Forecast
 - 8.3.5.1.1. By Value
 - 8.3.5.2. Market Share & Forecast
 - 8.3.5.2.1. By Product Type
 - 8.3.5.2.2. By Tumor Type
 - 8.3.5.2.3. By Indication
 - 8.3.5.2.4. By Treatment Type
 - 8.3.5.2.5. By Targeted Antigen
 - 8.3.5.2.6. By End User
- 8.3.6. Spain CAR-T Cell Therapy Market Outlook
 - 8.3.6.1. Market Size & Forecast
 - 8.3.6.1.1. By Value
 - 8.3.6.2. Market Share & Forecast
 - 8.3.6.2.1. By Product Type
 - 8.3.6.2.2. By Tumor Type
 - 8.3.6.2.3. By Indication
 - 8.3.6.2.4. By Treatment Type
 - 8.3.6.2.5. By Targeted Antigen
 - 8.3.6.2.6. By End User

9. ASIA-PACIFIC CAR-T CELL THERAPY MARKET OUTLOOK

- 9.1. Market Size & Forecast
 - 9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Product Type

9.2.2. By Tumor Type

9.2.3. By Indication

9.2.4. By Treatment Type

9.2.5. By Targeted Antigen

9.2.6. By End User

9.2.7. By Country

9.3. Asia-Pacific: Country Analysis

9.3.1. China CAR-T Cell Therapy Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Product Type

9.3.1.2.2. By Tumor Type

9.3.1.2.3. By Indication

9.3.1.2.4. By Treatment Type

9.3.1.2.5. By Targeted Antigen

9.3.1.2.6. By End User

9.3.2. Japan CAR-T Cell Therapy Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Product Type

9.3.2.2.2. By Tumor Type

9.3.2.2.3. By Indication

9.3.2.2.4. By Treatment Type

9.3.2.2.5. By Targeted Antigen

9.3.2.2.6. By End User

9.3.3. India CAR-T Cell Therapy Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Product Type

9.3.3.2.2. By Tumor Type

9.3.3.2.3. By Indication

9.3.3.2.4. By Treatment Type

9.3.3.2.5. By Targeted Antigen

9.3.3.2.6. By End User

9.3.4. Australia Global CAR-T Cell Therapy Market Outlook

9.3.4.1. Market Size & Forecast

9.3.4.1.1. By Value

9.3.4.2. Market Share & Forecast

9.3.4.2.1. By Type

9.3.4.2.2. By Product Type

9.3.4.2.3. By Technology

9.3.4.2.4. By Duration

9.3.4.2.5. By Application

9.3.4.2.6. By End User

9.3.5. South Korea Global CAR-T Cell Therapy Market Outlook

9.3.5.1. Market Size & Forecast

9.3.5.1.1. By Value

9.3.5.2. Market Share & Forecast

9.3.5.2.1. By Type

9.3.5.2.2. By Product Type

9.3.5.2.3. By Technology

9.3.5.2.4. By Duration

9.3.5.2.5. By Application

9.3.5.2.6. By End User

10. SOUTH AMERICA CAR-T CELL THERAPY MARKET OUTLOOK

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Product Type

10.2.2. By Tumor Type

10.2.3. By Indication

10.2.4. By Treatment Type

10.2.5. By Targeted Antigen

10.2.6. By End User

10.2.7. By Country

10.3. South America: Country Analysis

10.3.1. Brazil CAR-T Cell Therapy Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Type

- 10.3.1.2.2. By Product Type
- 10.3.1.2.3. By Technology
- 10.3.1.2.4. By Duration
- 10.3.1.2.5. By Application
- 10.3.1.2.6. By End User
- 10.3.2. Argentina CAR-T Cell Therapy Market Outlook
 - 10.3.2.1. Market Size & Forecast
 - 10.3.2.1.1. By Value
 - 10.3.2.2. Market Share & Forecast
 - 10.3.2.2.1. By Type
 - 10.3.2.2.2. By Product Type
 - 10.3.2.2.3. By Technology
 - 10.3.2.2.4. By Duration
 - 10.3.2.2.5. By Application
 - 10.3.2.2.6. By End User
- 10.3.3. Colombia CAR-T Cell Therapy Market Outlook
 - 10.3.3.1. Market Size & Forecast
 - 10.3.3.1.1. By Value
 - 10.3.3.2. Market Share & Forecast
 - 10.3.3.2.1. By Type
 - 10.3.3.2.2. By Product Type
 - 10.3.3.2.3. By Technology
 - 10.3.3.2.4. By Duration
 - 10.3.3.2.5. By Application
 - 10.3.3.2.6. By End User

11. MIDDLE EAST & AFRICA CAR-T CELL THERAPY MARKET OUTLOOK

- 11.1. Market Size & Forecast
 - 11.1.1. By Value
- 11.2. Market Share & Forecast
 - 11.2.1. By Product Type
 - 11.2.2. By Tumor Type
 - 11.2.3. By Indication
 - 11.2.4. By Treatment Type
 - 11.2.5. By Targeted Antigen
 - 11.2.6. By End User
 - 11.2.7. By Country
- 11.3. Middle East & Africa: Country Analysis

- 11.3.1. Israel CAR-T Cell Therapy Market Outlook
 - 11.3.1.1. Market Size & Forecast
 - 11.3.1.1.1. By Value
 - 11.3.1.2. Market Share & Forecast
 - 11.3.1.2.1. By Type
 - 11.3.1.2.2. By Product Type
 - 11.3.1.2.3. By Technology
 - 11.3.1.2.4. By Duration
 - 11.3.1.2.5. By Application
 - 11.3.1.2.6. By End User
- 11.3.2. Saudi Arabia CAR-T Cell Therapy Market Outlook
 - 11.3.2.1. Market Size & Forecast
 - 11.3.2.1.1. By Value
 - 11.3.2.2. Market Share & Forecast
 - 11.3.2.2.1. By Type
 - 11.3.2.2.2. By Product Type
 - 11.3.2.2.3. By Technology
 - 11.3.2.2.4. By Duration
 - 11.3.2.2.5. By Application
 - 11.3.2.2.6. By End User
- 11.3.3. UAE Global CAR-T Cell Therapy Market Outlook
 - 11.3.3.1. Market Size & Forecast
 - 11.3.3.1.1. By Value
 - 11.3.3.2. Market Share & Forecast
 - 11.3.3.2.1. By Type
 - 11.3.3.2.2. By Product Type
 - 11.3.3.2.3. By Technology
 - 11.3.3.2.4. By Duration
 - 11.3.3.2.5. By Application
 - 11.3.3.2.6. By End User
- 11.3.4. South Africa CAR-T Cell Therapy Market Outlook
 - 11.3.4.1. Market Size & Forecast
 - 11.3.4.1.1. By Value
 - 11.3.4.2. Market Share & Forecast
 - 11.3.4.2.1. By Type
 - 11.3.4.2.2. By Product Type
 - 11.3.4.2.3. By Technology
 - 11.3.4.2.4. By Duration
 - 11.3.4.2.5. By Application

11.3.4.2.6. By End User

12. MARKET DYNAMICS

12.1. Drivers

12.2. Challenges

13. MARKET TRENDS & DEVELOPMENTS

14. COMPETITIVE LANDSCAPE

14.1. Competition Outlook

14.2. Company Profiles

14.2.1. Gilead Sciences, Inc

14.2.2. Novartis International AG

14.2.3. Bristol Myers Squibb Co.

14.2.4. AbbVie Inc.

14.2.5. Cellectis SA

14.2.6. Amgen Inc

14.2.7. Pfizer Inc.

14.2.8. Merck & Co. Inc.

14.2.9. Intellia Therapeutics Inc.

14.2.10. Poseida Therapeutics Inc

14.2.11. Johnson & Johnson

14.2.12. Allogene Therapeutics Inc

14.2.13. Autolus Therapeutics PLC

14.2.14. Humanigen, Inc.

14.2.15. Sangamo Therapeutics, Inc.

15. STRATEGIC RECOMMENDATIONS

List Of Tables

LIST OF TABLES

Table 1: Global Cancer Statistics, 2020

Table 2: Total Number of New Cancer Cases and Deaths Reported Globally, By Type, 2020

Table 3: Details of FDA Approved CAR-T Cell Therapies (As of February 2022)

Table 4: North America Cancer Statistics, 2020

Table 5: Total Number of New Cancer Cases and Deaths Reported in North America, By Type, 2020

Table 6: Europe Cancer Statistics, 2020

Table 7: Total Number of New Cancer Cases and Deaths Reported in Europe, By Type, 2020

Table 8: Asia-Pacific Cancer Statistics, 2020

Table 9: Total Number of New Cancer Cases and Deaths Reported in Asia Pacific, By Type, 2020

Table 10: South America Cancer Statistics, 2020

Table 11: Total Number of New Cancer Cases and Deaths Reported in South America, By Type, 2020

Table 12: Middle East & Africa Cancer Statistics, 2020

Table 13: Total Number of New Cancer Cases and Deaths Reported in Middle East, By Type, 2020

List Of Figures

LIST OF FIGURES

Figure 1: Global CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 2: Global CAR-T Cell Therapy Market Share, By Product Type, By Value, 2017-2027F

Figure 3: Global CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 4: Global CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 5: Global CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 6: Global CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 7: Global CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 8: Global CAR-T Cell Therapy Market Share, By Region, By Value, 2017-2027F

Figure 9: Global CAR-T Cell Therapy Market Share, By Company, By Value, 2021

Figure 10: Global CAR-T Cell Therapy Market Map, By Product Type, Market Size (USD Million) & Growth Rate (%), 2021

Figure 11: Global CAR-T Cell Therapy Market Map, By Indication, Market Size (USD Million) & Growth Rate (%), 2021

Figure 12: Global CAR-T Cell Therapy Market Map, By Region, Market Size (USD Million) & Growth Rate (%), 2021

Figure 13: North America CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 14: North America CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 15: North America CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 16: North America CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 17: North America CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 18: North America CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 19: North America CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2027F

Figure 20: United States CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 21: United States CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 22: United States CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 23: United States CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 24: United States CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 25: United States CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 26: Canada CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 27: Canada CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 28: Canada CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 29: Canada CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 30: Canada CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 31: Canada CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 32: Mexico CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 33: Mexico CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 34: Mexico CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 35: Mexico CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 36: Mexico CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 37: Mexico CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 38: Europe CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 39: Europe CAR-T Cell Therapy Market Share, By Tumor Type, By Value,

2017-2027F

Figure 40: Europe CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 41: Europe CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 42: Europe CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 43: Europe CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 44: Europe CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2027F

Figure 45: Germany CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 46: Germany CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 47: Germany CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 48: Germany CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 49: Germany CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 50: Germany CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 51: France CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 52: France CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 53: France CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 54: France CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 55: France CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 56: France CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 57: Switzerland CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 58: Switzerland CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 59: Switzerland CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 60: Switzerland CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 61: Switzerland CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 62: Switzerland CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 63: United Kingdom CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 64: United Kingdom CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 65: United Kingdom CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 66: United Kingdom CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 67: United Kingdom CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 68: United Kingdom CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 69: Italy CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 70: Italy CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 71: Italy CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 72: Italy CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 73: Italy CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 74: Italy CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 75: Spain CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 76: Spain CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 77: Spain CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 78: Spain CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 79: Spain CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 80: Spain CAR-T Cell Therapy Market Share, By End User, By Value,

2017-2027F

Figure 81: Asia-Pacific CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 82: Asia-Pacific CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 83: Asia-Pacific CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 84: Asia-Pacific CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 85: Asia-Pacific CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 86: Asia-Pacific CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 87: Asia-Pacific CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2027F

Figure 88: China CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 89: China CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 90: China CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 91: China CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 92: China CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 93: China CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 94: Japan CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 95: Japan CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 96: Japan CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 97: Japan CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 98: Japan CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 99: Japan CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 100: India CAR-T Cell Therapy Market Size, By Value (USD Million),

2017-2027F

Figure 101: India CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 102: India CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 103: India CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 104: India CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 105: India CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 106: Australia CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 107: Australia CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 108: Australia CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 109: Australia CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 110: Australia CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 111: Australia CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 112: South Korea CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 113: South Korea CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 114: South Korea CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 115: South Korea CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 116: South Korea CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 117: South Korea CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 118: South America CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 119: South America CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 120: South America CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 121: South America CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 122: South America CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 123: South America CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 124: South America CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2027F

Figure 125: Brazil CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 126: Brazil CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 127: Brazil CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 128: Brazil CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 129: Brazil CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 130: Brazil CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 131: Argentina CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 132: Argentina CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 133: Argentina CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 134: Argentina CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 135: Argentina CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 136: Argentina CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 137: Colombia CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 138: Colombia CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 139: Colombia CAR-T Cell Therapy Market Share, By Indication, By Value,

2017-2027F

Figure 140: Colombia CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 141: Colombia CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 142: Colombia CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 143: Middle East & Africa CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 144: Middle East & Africa CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 145: Middle East & Africa CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 146: Middle East & Africa CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 147: Middle East & Africa CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 148: Middle East & Africa CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 149: Middle East & Africa CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2027F

Figure 150: Israel CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F

Figure 151: Israel CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F

Figure 152: Israel CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

Figure 153: Israel CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F

Figure 154: Israel CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F

Figure 155: Israel CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

Figure 156: Saudi Arabia CAR-T Cell Therapy Market S

I would like to order

Product name: Global CAR-T Cell Therapy Market, By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others), By Tumor Type (Hematological Malignancies, Solid Tumors), By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others), By Treatment Type (Single Treatment, Combination Treatment), By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), By Region, Competition, Forecast and Opportunities, 2017-2027

Product link: <https://marketpublishers.com/r/G6E787582DD0EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6E787582DD0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970